19:59:48 EST Wed 11 Nov 2026
Enter Symbol
or Name
USA
CA



Q:TGTX - TG THERAPEUTICS INC - https://www.tgtherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TGTX - Q0.965.76·65.820.365.76+1.502.32,058.6131,57321,10264.01  66.07  62.7963.60  26.7619:41:53Nov 0915 min RT 2¢

Recent Trades - Last 10 of 21102
Time ETExPriceChangeVolume
19:41:53Q65.821.5635
19:40:10Q65.7661.5061
19:40:10Q65.76011.50011
19:39:43Q65.741.4877
19:39:43Q65.741.4819
19:39:43Q65.741.485
19:39:43Q65.741.481
19:39:43Q65.741.481
19:39:43Q65.741.4892
19:39:43Q65.741.4823

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-11-09 07:00U:TGTXNews ReleaseTG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance
2026-11-02 07:30U:TGTXNews ReleaseTG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update
2026-10-23 10:55U:TGTXNews ReleaseTG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
2026-10-21 08:52U:TGTXNews ReleaseTG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
2026-10-12 07:30U:TGTXNews ReleaseTG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis
2026-10-08 07:30U:TGTXNews ReleaseTG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
2026-09-10 08:30U:TGTXNews ReleaseHistoric First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
2026-09-10 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-03 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the Cantor Global Healthcare Conference
2026-08-03 07:00U:TGTXNews ReleaseTG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI(TM) Revenue Guidance
2026-07-29 07:30U:TGTXNews ReleaseTG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update
2026-07-06 07:30U:TGTXNews ReleaseTG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
2026-06-24 08:30U:TGTXNews ReleaseThe Quest to Repair What Multiple Sclerosis Takes Away
2026-06-09 07:30U:TGTXNews ReleaseTG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
2026-06-03 07:30U:TGTXNews ReleaseTG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI(TM) (ublituximab-xiiy)
2026-06-02 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
2026-06-01 07:30U:TGTXNews ReleaseTG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
2026-05-28 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the Jefferies Global Healthcare Conference
2026-05-27 07:30U:TGTXNews ReleaseTG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
2026-05-26 07:30U:TGTXNews ReleaseTG Therapeutics Announces Data Presentations for BRIUMVI(TM) at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting